

# EZ-Tn5™ <R6K $\gamma$ ori/KAN-2>Tnp Transposome™ Kit

Cat. No. TSM08KR

Connect with Epicentre on our blog ([epicentral.blogspot.com](http://epicentral.blogspot.com)),  
Facebook ([facebook.com/EpicentreBio](https://facebook.com/EpicentreBio)), and Twitter ([@EpicentreBio](https://twitter.com/EpicentreBio)).

## 1. Introduction

The EZ-Tn5™ <R6K $\gamma$ ori/KAN-2>Tnp Transposome™ is the stable complex formed between the EZ-Tn5 Transposase enzyme and the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon. The EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon contains an R6K $\gamma$  conditional origin of replication (R6K $\gamma$ ori) and the Tn903 kanamycin resistance gene (KanR) that is functional in *E. coli*, flanked by hyperactive 19-basepair Mosaic End (ME) EZ-Tn5 Transposase recognition sequences. The EZ-Tn5 Transposome can be electroporated into living cells where the EZ-Tn5 Transposase is activated by Mg<sup>2+</sup> in the host's cellular environment resulting in random insertion of the EZ-Tn5 Transposon into the genomic DNA of the host.<sup>1,2</sup>


The R6K $\gamma$ ori makes this transposon useful for “rescue cloning” of the region of genomic DNA into which the transposon has been randomly inserted. An overview of the rescue cloning process is presented on page 2. Genomic DNA transposed with the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon is first purified and then fragmented, self-ligated and finally transformed into an *E. coli* host that expresses the *pir* gene product ( $\Pi$  protein).<sup>3</sup> When selected on kanamycin-containing plates, only the cells containing the <R6K $\gamma$ ori/KAN-2> Transposon will grow.

Unlabeled forward and reverse transposon-specific primers are supplied in the kit. These primers can be used for bidirectional DNA sequencing or mapping of transposon insertion sites in target genomic DNAs or rescue clones. Users may also subject sufficiently large rescue clones to transposon insertion reactions using the HyperMu™ <CHL-1> Insertion Kit and produce sequence from these transposon insertion sites in order to obtain full clone sequence coverage.

## 2. Product Specifications

**Storage:** Store only at –20°C in a freezer without a defrost cycle.

**Size:** Reagents included in the kit are sufficient for 10 *in vivo*<sup>†</sup> transposon insertion reactions.



**Figure 1. Rescue Cloning Overview.**

**Storage Buffer:** The EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Tnp Transposome is supplied in a 50% glycerol solution containing 27.5 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.3 mM EDTA, 0.05% Triton®X-100, and 0.5 mM dithiothreitol. The KAN-2 FP-1 Forward and R6KAN-2 RP-1 Reverse Primers are supplied in 10 mM Tris-HCl, (pH 7.5), 1 mM EDTA.

**Quality Control:** EZ-Tn5 <R6K $\gamma$ ori/KAN-2>Tnp Transposome activity is assayed by electroporation into a *recA*<sup>-</sup> *E. coli* host strain having a transformation efficiency of >10<sup>9</sup> cfu/μg DNA. Assays must yield >10<sup>5</sup> Kan<sup>R</sup> colonies/μg or >2.0 x 10<sup>3</sup> Kan<sup>R</sup> colonies/μl of transposome respectively. Primers are function-tested via PCR and in a DNA cycle sequencing reaction using the SequiTherm EXCEL™ II DNA Sequencing Kit and a plasmid containing an EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon as template.

**Contaminating Activity Assays:** All components of the EZ-Tn5 <R6K $\gamma$ ori/KAN-2>Tnp Transposome Kit are free of detectable DNase and RNase activities as judged by agarose gel electrophoresis following over-digestion assays with the exception of the inherent endonucleolytic function of the EZ-Tn5 Transposase.

### 3. Kit Contents

Desc.	Concentration	Quantity
EZ-Tn5™ <R6K $\gamma$ ori/KAN-2>Tnp Transposome™	@ 33 ng/μl	10 μl
KAN-2 FP-1 Forward Primer	@ 50 μM	20 μl
R6KAN-2 RP-1 Reverse Primer	@ 50 μM	20 μl
Sterile Water		1 ml

### 4. Related Products

The following products are also available:

- TransforMax™ EC100D™ *pir*<sup>+</sup> and *pir*-116 Electrocompetent *E. coli*
- End-It™ DNA End-Repair Kit
- Fast-Link™ DNA Ligation Kits
- MasterPure™ DNA Purification Kits
- EZ-Tn5™ Tnp Transposome™ Kits
- EZ-Tn5™ Transposase
- EZ-Tn5™ Transposons and Insertion Kits
- HyperMu™ Transposons and Insertion Kits

## 5. Rescue Cloning of EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposed Genomic DNA

An overview of the process for rescue cloning of the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon insertion site in genomic DNA is given below.

### Protocol

- 1. Electroporation of Host Cells with EZ-Tn5 <R6K $\gamma$ ori/KAN-2>Tnp Transposome and Selection of Transposition Clones:** Electroporate electrocompetent cells using 1  $\mu$ l of the EZ-Tn5 <R6K $\gamma$ ori/KAN-2>Tnp Transposome. The electrocompetent cells should have a transformation efficiency of  $>10^7$  cfu/ $\mu$ g of DNA, but use cells of the highest transformation efficiency possible to maximize the number of transposon insertion clones. Perform electroporation according to the equipment manufacturer's recommendations.

**Immediately** recover the electroporated cells after electroporation. Even slight delays in initiating the cell recovery process will result in a reduced number of transposition clones. For *E. coli*, add SOC medium to the electroporation cuvette to 1 ml final volume **immediately** after electroporation. Pipette the medium/cells gently to mix. Transfer to a tube and incubate on a 37°C shaker for 30-60 minutes to facilitate cell outgrowth.

If working with *E. coli*, dilute aliquots of the recovered cells (e.g., 1:10 and 1:100). Plate 100  $\mu$ l of undiluted cells and each cell dilution separately on plates containing 50  $\mu$ g/ml kanamycin. Other species may require plating of undiluted cells on plates containing 25-50  $\mu$ g/ml kanamycin. Store the unused portion of the electroporated cells at +4°C for up to 2 days in the event that additional plates need to be prepared. The number of Kan<sup>R</sup> colonies/ $\mu$ l of EZ-Tn5 <R6K $\gamma$ ori/KAN-2>Tnp Transposome will be dependent on the transformation efficiency of the cells used and the level of expression of the Tn903 kanamycin resistance marker in that species. Select transposition clones for "rescue cloning" by any of a number of methods including observing a desired phenotypic change, Southern Blot analysis or selecting for a desired "gene knockout".

- 2. Preparation of Transposed Genomic DNA from Host Cells:** Prepare genomic DNA from chosen clones, for example, using the MasterPure DNA Purification Kit. Fragment 1  $\mu$ g of the genomic DNA by random shearing or by restriction endonuclease digestion(s) (See page 5 for the restriction map of the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon in order to avoid restriction within the transposon). If desired, size-select the fragmented genomic DNA (e.g., by low-melting point agarose gel electrophoresis). Genomic DNA that has been fragmented by random shearing or by digestion with two different restriction endonucleases must be end-repaired (made blunt-ended) and 5'-phosphorylated in order to be self-ligated. End-repair and 5'-phosphorylate the DNA as necessary (e.g., by using the End-It™ DNA End-Repair Kit [Epicentre]).
- 3. Ligation of Fragmented Genomic DNA:** Self-ligate 0.1-1  $\mu$ g of DNA using 2 U of T4 DNA Ligase in 10-20  $\mu$ l total volume for 1 hour at room temperature. The extent of ligation can be quickly monitored by running aliquots of the reaction before and after addition of the T4 DNA Ligase addition, on an agarose gel. Terminate the reaction and inactivate the T4 DNA Ligase by heating at 70°C for 10 minutes.

4. **Transformation and Selection of Rescue Clones:** Electroporate electrocompetent *pir E. coli* (*E. coli* expressing the  $\Pi$  protein, e.g. TransforMax EC100D *pir*<sup>+</sup> or TransforMax EC100D *pir*-116 Electrocompetent *E. coli*) using 1-2  $\mu$ l of the ligation mix. Recover the electroporated cells by adding SOC medium to the electroporation cuvette to 1 ml final volume **immediately** after electroporation. Pipette the medium/cells gently to mix. Transfer to a tube and incubate on a 37°C shaker for 30-60 minutes to facilitate cell outgrowth. Plate cells on LB agar containing 50  $\mu$ g/ml of kanamycin. Select Kan<sup>R</sup> colonies overnight.
5. **DNA Sequencing of Rescue Clones:** Unlabeled forward and reverse EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon-specific primers are supplied in the kit. These primers can be used for bidirectional DNA sequencing or mapping of transposon insertion sites in target genomic DNAs or rescue clones. For DNA sequencing rescue clones containing inserts too large to be completely sequenced using only the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon-specific primers, users may subject these clones to *in vitro* transposon insertion reactions using the HyperMu <CHL-1> Insertion Kit, and generating DNA sequence from the provided HyperMu <CHL-1> Transposon-specific primers in order to obtain full insert sequence coverage.

## 6. Primer Information

### KAN-2 FP-1 Forward Primer

5' - ACCTACAACAAAGCTCTCATCAACC - 3'

**Length:** 25 nucleotides

**G+C content:** 11

**Molecular Weight:** 7,484 daltons

#### Temperatures of Dissociation & Melting:

$T_d$ : 68°C (nearest neighbor method)

$T_m$ : 73°C (% G+C method)

$T_m$ : 72°C ([2 (A+T) + 4 (G+C)] method)

$T_m$ : 63°C ((81.5 + 16.6 (log [Na<sup>+</sup>])) +  
([41 (#G+C) - 500] / length) method)

where [Na<sup>+</sup>] = 0.1 M

**R6KAN-2 RP-1 Reverse Primer**

**5' - CTACCCTGTGGAACACCTACATCT - 3'**

**Length:** 24 nucleotides

**G+C content:** 12

**Molecular Weight:** 7,210 daltons

**Temperatures of Dissociation & Melting:**

$T_d$ : 66°C (nearest neighbor method)

$T_m$ : 74°C (% G+C method)


$T_m$ : 72°C ( $[(2(A+T) + 4(G+C))]$  method)

$T_m$ : 65°C ( $((81.5 + 16.6(\log [Na^+]))) +$   
 $([41(\#G+C) - 500] / \text{length})$  method)

where  $[Na^+] = 0.1 M$

**EZ-Tn5™ <R6K $\gamma$  ori / KAN-2> Transposon**

(2001 bp.)



Note: Not all restriction enzymes that cut only once are indicated above.

See the following pages for further information.

Primers are not drawn to scale.

R6KAN-2 RP-1 Reverse Primer

KAN-2 FP-1 Forward Primer

ME = Mosaic End

5' CTACCCTGTGGAACACCTACATCT 3'

5' ACCTACAACAAAGCTCTCATCAACC 3'

5' AGATGTGTATAAGAGACAG 3'

**Figure 2.** EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon.

**Restriction Enzymes that cut the EZ-Tn5 <R6Kγori/KAN-2> Transposon 1 to 3 times:**

<b>Enzyme</b>	<b>Sites</b>	<b>Location</b>	<b>Enzyme</b>	<b>Sites</b>	<b>Location</b>
Acc I	1	1952	Fau I	2	673, 1928
Apo I	2	962, 1146	Fsp I	2	709, 807
Ase I	2	339, 1548	Hae I	2	719, 1436
AsiS I	1	1349	Hae II	1	521
Ava I	2	736, 947	Hae III	3	719, 953, 1436
Ava II	3	681, 723, 1902	Hinc II	1	1953
BamH I	1	1939	Hind III	2	416, 1969
Ban II	1	1004	Mly I	2	1582, 1958
Bbs I	1	568	Msc I	1	719
Bfa I	2	674, 1946	Msl I	2	508, 703
BfrB I	2	1197, 1463	Nci I	2	679, 1222
BfuA I	1	1964	Nla IV	3	682, 725, 1941
Bpu10 I	2	581, 1366	Nru I	1	1006
BsaA I	3	176, 198, 308	Nsi I	2	1199, 1465
BsaB I	1	95	Nsp I	1	1967
BsaW I	3	99, 497, 1484	PaeR7 I	1	947
BsiE I	1	1349	PflM I	2	798, 1612
BsiHKA I	1	700	Ple I	2	1581, 1957
Bsm I	3	808, 1233, 1310	PpuM I	2	681, 723
BsmB I	1	1365	Psi I	1	385
Bsp1286 I	2	700, 1004	Pst I	1	1961
BspD I	2	29, 1040	Pvu I	1	1349
BspE I	2	99, 497	Sal I	1	1951
BspH I	1	867	Sau96 I	3	681, 723, 1902
BspM I	1	1964	Sbf I	1	1961
BsrD I	1	841	Sfc I	1	1957
BsrF I	1	1303	Sim I	2	681, 723
BstDS I	3	718, 1873, 1934	Sml I	1	947
Btg I	3	714, 1869, 1930	SnaB I	1	176
Bts I	2	1210, 1297	Sph I	1	1967
Clal	2	29, 1040	Ssp I	1	1274
Dra I	1	414	Sty I	1	792
Dra III	1	818	Tli I	1	947
Dsa I	3	714, 1869, 1930	Tsp45 I	1	1496
Eae I	1	717	TspRI	3	1222, 1297, 1769
Ear I	1	1162	Xba I	1	1945
EcoN I	1	1261	Xho I	1	947
EcoO109 I	2	681, 723	Xmn I	1	38

**Restriction Enzymes that cut the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon 4 or more times:**

Aci I	Cac8 I	HpyCH4 IV	Rsa I
Alu I	CviJ I	HpyCH4 V	Sau3A I
Alw I	Dde I	Mae II	ScrF I
BsaI I	Dpn I	Mae III	SfaN I
Bsl I	Fnu4H I	Mbo I	Taq I
BsmA I	Hha I	Mbo II	Tfi I
Bsr I	Hinf I	Mnl I	Tse I
BssK I	HinP I	Mse I	Tsp4C I
BstF5 I	Hpa II	Msp I	Tsp509 I
BstN I	Hph I	Mwo I	
BstU I	Hpy188 I	Nla III	
BstY I	HpyCH4 III	PspG I	

**Restriction Enzymes that do not cut the EZ-Tn5 <R6K $\gamma$ ori/KAN-2> Transposon:**

Aat II	Bcl I	BstB I	Nae I	SanD I
Acc65 I	Bgl I	BstE II	Nar I	Sap I
Acl I	Bgl II	BstX I	Nco I	Sca I
Afe I	Blp I	BstZ17 I	Nde I	SexA I
Afl II	Bme1580 I	Bsu36 I	NgoM IV	Sfi I
Afl III	BmgB I	Drd I	Nhe I	Sfo I
Age I	Bmr I	Eag I	Not I	SgrA I
Ahd I	Bsa I	Eco47 III	Pac I	Sma I
Ale I	BsaH I	EcoR I	Pci I	Spe I
AlwN I	BseY I	EcoR V	PflF I	Srf I
Apa I	BsiW I	Fse I	Pme I	Sse8647 I
ApaB I	BspLU11 I	Gdi II	Pml I	Stu I
ApaL I	BsrB I	Hpa I	PshA I	Swa I
Asc I	BsrD I	Hpy99 I	PspOM I	Tat I
Avr II	BsrG I	Kpn I	Pvu II	Tth111 I
Ban I	BssH II	Mfe I	Rsr II	Xcm I
BbvC I	BssS I	Mlu I	Sac I	Xma I
BciV I	BstAP I	MspA1 I	Sac II	



EZ-Tn5™ <R6K<sub>Yori</sub>/KAN-2> Transposon 2,001 bp.

1 CTGTCCTCTTA TACACATCTC AACCATCATC GATGAATTGC TTTCGTTAAATA CAGATGTAGG TGTTCACACAG  
 71 GGTAGCCAG ACCATCTCGC GATGCAGATC CGGATGCCAT TTTCATTAACCT CTTTCTCCGC ACCGCACATA  
 141 GATCCGAAGA TCAGCAGTTC AACCTGTTGA TAGTACGGTAC TAAGCTCTCA TGTTTCACGT ACTAAGCTCT  
 211 CATGTTTAAAC GTACTAAGCT CTCATGTTTTA ACGAACTAAA CCCTCATGGC TAACGTACTA AGCTCTCATG  
 281 GCTAACGTAC TAAAGCTCTCA TGTTTCACGT ACTAAGCTCT CATGTTTTGAA CAATAAAAT ATATAAATC  
 351 AGCAACTTAA AFAGCCTCTA AGGTTTTAAG TTTTATAAGA AAAAAAGAA TATATAAGC TTTTAAAGT  
 421 TTTAAAGGTTT AACGGTTGTG GACAACAAGC CAGGGATCTG CCATTTCAAT ACCTCTTCT CCGCACCGA  
 491 CATAGATCCG GAACATAATG GTGCAGGGCG CTGACTTCCG CGTTTCCAGA CTTTACGAAA CACGGAAACC  
 561 GAAAGACCAAT CATGTTGTTG CTCAGGTCGC AGACGTTTTG CAGCAGCAGT CGCTTACGT TCGCTCGGT  
 631 ATCCGGTGAT CATTCCTGTA ACCAGTAAG CAACCCCGCC AGCCTAGCCG GGTCTCAAC GACAGAGCA  
 701 CGATCATGCG CACCCGTGGC CAGGACCCAA CGCTGCCCGC GATGCGCTGC TGGAGATGGC  
 771 GGACGGCATG GATATGTTCT GCCAAGGTTT GGTTTGGCA TTTACAGGGT GTCTCAAAT CTCTGATGTT  
 841 ACATTTGCACA AGATAAAAAT ATATCATCAT GAACAATAAA ACTGTCTGCT TACATAAACA GTAATACAAG  
 911 GGGTGTATG ACCATAATTC AACGGGAAAC GTCTTTGCTCG AGGCCCGCAT TAAAATCCAA CATGGATGTT  
 981 GATTTATATG GGTATAAATG GGCTCGCGAT AATGTCGGC AATCAGGTGC GACAATCTAT CGATTTGATG  
 1051 GGAAGCCCGA TCGGCCAGAG TTGTTTCTGA AACATGGCAA AGGTAGCGTT GCCAATGATG TTACAGATGA  
 1121 GATGGTCAGA CTAAACTGGC TGACGGAAAT TATGCTCTTT CCGACCATCA AGCATTTTAT CCGTACTCTT  
 1191 GATGATGCAT GGTACTCAC CACTGCGATC CCGGGAAAA CAGCAITCCA GGTATTAGAA GAATATCTGT  
 1261 ATTCAGGTGA AAATATTTGT GATCGCTGG CAGTGTCTCT GCGCCGGTTG CATTCGATTC CTGTTTGTAA  
 1331 TGTCTCTTT AACAGCGATC CGGTATTTCC TCTCGCTCAG GCGCAATCAC GAATGAATAA CCGTTTGGTT  
 1401 GATGCGAGTG APTTTGATGA CGAGCGTAAT GGTGCGCTT TTGAACAAGT CTGGAAGAA ATGCAATAAC  
 1471 TTTTGCCATT CTCACCGGAT TCAGTCGTCA TCTACTGTTG TTTTCTCATT GATAACCTTA TTTTGGACGA  
 1541 GGGGAAATA ATAGGTTGTA TTGATGTTGG ACGAGTCGGA ATCGCAGACC GATACCAGGA TCTTTGCCATC  
 1611 CTATGGAAT GCCTCGGTGA GTTTTCTCTT TCATTACAGA AACGGCTTTT TCAAAAATAT GGTATTGATA  
 1681 ATCTGTGAT GAATAAATG CAGTTTCAAT TGATGCTCGA TGAGTTTTTC TAATCAGAA TGGTTAATG  
 1751 GTGTAAAC TGGCAGAGCA TTACGCTGAC TTGACGGGAC GCGGGCTTTG TTGAATAAAT CGAACTTTG  
 1821 CTGAGTTGAA GGATCAGATC ACGCATCTT CCGACAACCG AGACCGTCTC GTGGCAAAGC AAAAGTTCAA  
 1891 AATCACCAAC TGGTCCACCT ACAACAAAAG TCTCATCAAC CGTGGCGGGG ATCTCTTAGA GTCGACCTGC  
 1961 AGCCATGCAA GCTTCAGGGT TGAGATGTTG ATAAGAGACA G

The transposon sequence can be downloaded at [www.epibio.com/sequences](http://www.epibio.com/sequences).

## 7. References

1. Hoffman, L.M. and Jendrisak, J. (1999) *Epicentre Forum*, **6** (3), 1.
2. Goryshin, I.Y. *et al.*, (2000) *Nat. Biotechnol.* **18**, 97.
3. Metcalf, W.W. *et al.*, (1994) *Gene*, **138**, 1.

*EC100D, End-It, EZ-Tn5, Fast-Link, HyperMu, MasterPure, SequiTherm EXCEL, TransforMax, and Transposome are trademarks of Epicentre, Madison, Wisconsin.*

*Triton is a registered trademark of Rohm & Haas, Philadelphia, Pennsylvania.*

*Use of Transposome™ Complexes for in vivo Transposon Insertion, including, but not limited to EZ-Tn5™ and HyperMu™ Transposome™ complexes, is covered by U.S. Patent Nos. 6,159,736 and 6,294,385; European Patent No. 1115856 and other patents issued or pending, exclusively licensed to Epicentre. These products are accompanied by a limited non-exclusive license for nonprofit organizations to use the purchased products solely for life science research. Specifically, researchers at nonprofit organizations may use these products in their research and they may transfer derivatives of the products to colleagues at other nonprofit organizations provided that such colleagues agree in writing to be bound by the terms and conditions of this label license. Researchers may not transfer these products or its derivatives to researchers at other organizations that are not nonprofit organizations without the express written consent of Epicentre and without those entities having an express license from Epicentre for the use of the products. Other than as specifically provided here, an authorized transferee of these products shall have no right to transfer these products or its derivatives to any other person or entity. A nonprofit organization performing research using this product for a for-profit organization shall also be considered for-profit. For-profit entities purchasing these products shall have three (3) months to evaluate the products in their research. Thereafter, such for-profit entities shall either contact Epicentre and take a license for their continued use of the products or destroy the products and all derivatives thereof. Please contact Epicentre with respect to licenses for commercial use, including manufacturing, therapeutic or diagnostic use.*

Visit our technical blog: [epicentral.blogspot.com](http://epicentral.blogspot.com)